So the TOGETHER trial signal boosted by Scott of slate star codex found Fluvoxamine to be effective at reducing 30% of COVID hospitalisation and fatality.
The NIH looked at the study and found it unconvicing, I am a bit confused as to the rationale.
I'll list it out as I understand it:
- the primary outcomes [retention in the emergency department for >6 hours or admission to a tertiary hospital] was chosen without rationale
- There was no significant difference in mortality between study arms in the intention-to-treat (ITT) population [however, it's 2% in treatment arm and 3% in placebo arm as expected of the 30% reduction expectation]
- significant difference was only found in patients who have persisted in taking >80% of fluvoxamine doses, however there were also improved outcome for patients who have persisted in taking >80% of placebo dose, suggesting that another mechanism [e.g. conscientiousness] to be resposible for [most? all?] the improvement in outcome.
Is my understanding correct and does NIH's critiques of the study hold merrit?